TissueLabs is a Swiss biotechnology company based in Bellinzona.Listek, Vanesa (2021-10-16). "Bioprinting Startup TissueLabs Moves HQ from Brazil to Switzerland". 3DPrint.com. Retrieved 2026-04-01. The company focuses on tissue engineering and biofabrication and develops 3D bioprinters and tissue-specific biomaterials for use in laboratory research applications including drug testing, disease modeling and cell culture.Listek, Vanesa (2021-12-02). "New Masked SLA Bioprinter Revealed by TissueLabs". 3DPrint.com. Retrieved 2026-04-01.
History TissueLabs was founded in January 2019 in Brazil by Gabriel Liguori and Emerson Moretto."Gabriel Liguori". MIT Technology Review Innovators Under 35. Retrieved 2026-04-01.Riga, Matheus (2021-07-01). "Healthtech brasileira está no caminho para viabilizar impressão em 3D de órgãos humanos". Forbes Brasil (in Brazilian Portuguese). Retrieved 2026-04-01. The company originated in the IPEN-Cietec incubator at the University of São Paulo and raised approximately $1.6 million in seed funding during its initial phase of development. In 2021, the company relocated its headquarters to Switzerland, initially based in Manno before moving to Bellinzona.
Early development During its early development, TissueLabs focused on laboratory tools for tissue engineering research.
In 2019, the company introduced MatriXpec, a line of tissue-specific hydrogels derived from decellularized extracellular matrix, developed for use in three-dimensional cell culture and bioprinting. By 2020, formulations had been developed for tissue types including myocardium, lung, liver, kidney, skin, and cartilage."Estas empresas vão mudar a forma como cuidamos da nossa saúde". Época Negócios (in Brazilian Portuguese). 2022-08-24. Retrieved 2026-04-01.
In 2020, TissueLabs introduced TissueStart, an extrusion-based 3D bioprinter designed for academic and laboratory use.
In early 2020, during the COVID-19 pandemic, it developed MatriWell, an in vitro system combining a cell culture insert with lung-derived hydrogels to model aspects of lung epithelium. The system was made for research use in studies of SARS-CoV-2 infection in pulmonary cells."TissueLabs: New 3D Printed Platform Free to Researchers Studying COVID-19". 3DPrint.com. 2020. Retrieved 2026-04-01. MatriWell was also used in a 2023 peer-reviewed research examining three-dimensional models for respiratory disease investigation.
Growth In 2021, TissueLabs introduced TissueRay, an MSLA-based 3D bioprinter. The system was presented at the 6th Tissue Engineering and Regenerative Medicine International Society (TERMIS) World Congress.
In 2023, the company closed a pre-seed financing round of $800,000, led by Mergus Ventures, with participation from MIT Angels and others. The funds supported the establishment of a new biofabrication facility in Bellinzona, which began operations in early 2024."TissueLabs begins biofabrication activities in Bellinzona". Greater Zurich Area. 2024-03-25. Retrieved 2026-04-01. Initially based in Manno, the relocation to Bellinzona was related to being closer to European biotech and research networks.
In 2024, TissueLabs was selected to participate in the Venture Leaders Biotech program, a Swiss initiative supporting early-stage biotechnology companies.
In 2025, TissueLabs introduced TissuePro, a 3D bioprinter with five independent extrusion heads designed for more complex tissue engineering applications.Duran, Paloma (2025-06-12). "TissueLabs Scales Bioprinting with Launch of TissuePro: Technical Specifications". 3D Printing Industry. Retrieved 2026-04-01."TissueLabs launches new TissuePro extrusion-based bioprinter". VoxelMatters. 2025-06-02. Retrieved 2026-04-01. It was also included in the Top 100 Startups to Watch list published by Pequenas Empresas & Grandes Negócios (PEGN) that year."Conheça as 100 Startups to Watch 2025". Pequenas Empresas & Grandes Negócios. 2025. Retrieved 2026-04-01.
Research According to statements by the company and its founder, TissueLabs is pursuing long-term research into the development of a bioartificial heart using patient-derived cells. In a 2021 interview, Liguori stated that clinical trials for such a device could require an additional 10–15 years of research and development.
See also
3D bioprinting
References
External links Official website